Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBaune, B.-
dc.identifier.citationNeuropsychiatric Disease and Treatment, 2008; 4(6):1181-1192-
dc.description.abstractQuetiapine has demonstrated efficacy in schizophrenia, bipolar disorder and in the treatment of specific symptom clusters such as agitation and sleep problems in mood disorders. In this review, randomized controlled studies demonstrating efficacy, safety and tolerability of quetiapine in major depressive disorder (MDD) and general anxiety disorder (GAD) are evaluated. The results show that quetiapine monotherapy and quetiapine augmentation of antidepressant treatment in MDD and GAD are efficacious for short-term and maintenance treatment at a dose range between 50 and 300 mg/day. Quetiapine appears to have a specific but overall mild side-effect profile, though, some adverse effects such as sedation and somnolence may lead to withdrawal from treatment in some patients. Overall, the available evidence suggests that there is a significant role for quetiapine in the treatment of MDD and GAD.-
dc.description.statementofresponsibilityBernhard T. Baune-
dc.publisherDove Medical Press Ltd.-
dc.rights© 2008 Dove Medical Press Limited. All rights reserved.-
dc.subjectmajor depressive disorders-
dc.subjectgeneral anxiety disorder-
dc.subjectrandomized controlled studies-
dc.subjectadverse effects-
dc.titleNew developments in the management of major depressive disorder and generalized anxiety disorder: role of quetiapine-
dc.typeJournal article-
dc.identifier.orcidBaune, B. [0000-0001-6548-426X]-
Appears in Collections:Aurora harvest
Psychiatry publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.